\begin{longtable}{p{0.16\textwidth}p{0.14\textwidth}p{0.14\textwidth}p{0.14\textwidth}p{0.14\textwidth}p{0.14\textwidth}p{0.14\textwidth}}
   & Trulicity & Mounjaro & Bydureon & Byetta & Soliqua & Unknown \\ 
  \hline 
\endfirsthead 
\multicolumn{7}{p{\textwidth}}{{ \bfseries \tablename \thetable{} -- continued from previous page}} \ 
\hline Feature & Trulicity & Mounjaro & Bydureon & Byetta & Soliqua & Unknown\\ \hline 
\endhead 
\hline \multicolumn{7}{p{\textwidth}}{{Continued on next page}} \\ \hline 
\endfoot 
\hline 
\endlastfoot 
 \hline
 & (N=68331) & (N=14118) & (N=3360) & (N=348) & (N=1612) & (N=4582) \\ 
  Age &  &  &  &  &  &  \\ 
    Mean (SD) & 60 (13) & 52 (13) & 60 (13) & 62 (12) & 65 (12) & 58 (12) \\ 
  Age Group &  &  &  &  &  &  \\ 
    0-17 & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    18-44 & 8339 (12\%) & 4075 (29\%) & 421 (13\%) & 33 (9\%) & 110 (7\%) & 645 (14\%) \\ 
    45-64 & 34448 (50\%) & 7654 (54\%) & 1655 (49\%) & 179 (51\%) & 666 (41\%) & 2484 (54\%) \\ 
    65+ & 25544 (37\%) & 2389 (17\%) & 1284 (38\%) & 136 (39\%) & 836 (52\%) & 1453 (32\%) \\ 
  Sex &  &  &  &  &  &  \\ 
    Female & 37232 (54\%) & 10103 (72\%) & 1841 (55\%) & 208 (60\%) & 830 (51\%) & 2573 (56\%) \\ 
    Male & 31003 (45\%) & 4008 (28\%) & 1510 (45\%) & 140 (40\%) & 781 (48\%) & 1993 (43\%) \\ 
    Unknown & 96 (0\%) & 7 (0\%) & 9 (0\%) & 0 (0\%) & 1 (0\%) & 16 (0\%) \\ 
  Race &  &  &  &  &  &  \\ 
    White & 47168 (69\%) & 10667 (76\%) & 2344 (70\%) & 262 (75\%) & 1050 (65\%) & 3307 (72\%) \\ 
    Black & 11448 (17\%) & 1812 (13\%) & 482 (14\%) & 31 (9\%) & 380 (24\%) & 795 (17\%) \\ 
    Asian & 2107 (3\%) & 211 (1\%) & 111 (3\%) & 9 (3\%) & 38 (2\%) & 119 (3\%) \\ 
    AI or AN & 448 (1\%) & 82 (1\%) & 33 (1\%) & 4 (1\%) & 6 (0\%) & 55 (1\%) \\ 
    NH or PI & 311 (0\%) & 37 (0\%) & 19 (1\%) & 1 (0\%) & 5 (0\%) & 13 (0\%) \\ 
    Other Race & 4167 (6\%) & 866 (6\%) & 215 (6\%) & 24 (7\%) & 72 (4\%) & 162 (4\%) \\ 
    Declined to answer & 676 (1\%) & 108 (1\%) & 40 (1\%) & 2 (1\%) & 17 (1\%) & 19 (0\%) \\ 
    Unknown & 2006 (3\%) & 335 (2\%) & 116 (3\%) & 15 (4\%) & 44 (3\%) & 112 (2\%) \\ 
  Ethnicity &  &  &  &  &  &  \\ 
    Hispanic or Latino & 7929 (12\%) & 1607 (11\%) & 483 (14\%) & 41 (12\%) & 182 (11\%) & 272 (6\%) \\ 
    Not Hispanic or Latino & 55844 (82\%) & 11845 (84\%) & 2592 (77\%) & 286 (82\%) & 1305 (81\%) & 3975 (87\%) \\ 
    Declined to answer & 837 (1\%) & 134 (1\%) & 48 (1\%) & 2 (1\%) & 19 (1\%) & 38 (1\%) \\ 
    Unknown & 3721 (5\%) & 532 (4\%) & 237 (7\%) & 19 (5\%) & 106 (7\%) & 297 (6\%) \\ 
  T2D & 60950 (89\%) & 6680 (47\%) & 2879 (86\%) & 282 (81\%) & 1461 (91\%) & 4374 (95\%) \\ 
  Obesity or Overweight & 52972 (78\%) & 12597 (89\%) & 1985 (59\%) & 209 (60\%) & 903 (56\%) & 3794 (83\%) \\ 
  Period &  &  &  &  &  &  \\ 
    2018 Jan-Jun & 3508 (5\%) & 0 (0\%) & 326 (10\%) & 32 (9\%) & 105 (7\%) & 1227 (27\%) \\ 
    2018 Jul-Dec & 4040 (6\%) & 0 (0\%) & 406 (12\%) & 75 (22\%) & 121 (8\%) & 1013 (22\%) \\ 
    2019 Jan-Jun & 5309 (8\%) & 0 (0\%) & 419 (12\%) & 62 (18\%) & 118 (7\%) & 774 (17\%) \\ 
    2019 Jul-Dec & 4982 (7\%) & 0 (0\%) & 295 (9\%) & 19 (5\%) & 112 (7\%) & 676 (15\%) \\ 
    2020 Jan-Jun & 4797 (7\%) & 0 (0\%) & 312 (9\%) & 17 (5\%) & 127 (8\%) & 426 (9\%) \\ 
    2020 Jul-Dec & 5903 (9\%) & 0 (0\%) & 512 (15\%) & 36 (10\%) & 185 (11\%) & 152 (3\%) \\ 
    2021 Jan-Jun & 8542 (13\%) & 0 (0\%) & 516 (15\%) & 47 (14\%) & 209 (13\%) & 130 (3\%) \\ 
    2021 Jul-Dec & 7793 (11\%) & 0 (0\%) & 241 (7\%) & 18 (5\%) & 168 (10\%) & 52 (1\%) \\ 
    2022 Jan-Jun & 8524 (12\%) & 104 (1\%) & 153 (5\%) & 16 (5\%) & 171 (11\%) & 51 (1\%) \\ 
    2022 Jul-Dec & 7981 (12\%) & 6531 (46\%) & 96 (3\%) & 15 (4\%) & 150 (9\%) & 43 (1\%) \\ 
    2023 Jan-Jun & 6952 (10\%) & 7483 (53\%) & 84 (2\%) & 11 (3\%) & 146 (9\%) & 38 (1\%) \\ 
    2023 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
  Atrial Fibrilation & 6128 (9\%) & 710 (5\%) & 251 (7\%) & 25 (7\%) & 156 (10\%) & 385 (8\%) \\ 
  Asthma & 11455 (17\%) & 2804 (20\%) & 518 (15\%) & 52 (15\%) & 201 (12\%) & 821 (18\%) \\ 
  CKD & 13407 (20\%) & 1225 (9\%) & 518 (15\%) & 44 (13\%) & 420 (26\%) & 771 (17\%) \\ 
  COPD & 7161 (10\%) & 721 (5\%) & 297 (9\%) & 27 (8\%) & 175 (11\%) & 579 (13\%) \\ 
  Glaucoma & 2080 (3\%) & 202 (1\%) & 106 (3\%) & 9 (3\%) & 67 (4\%) & 136 (3\%) \\ 
  Heart Failure & 7935 (12\%) & 711 (5\%) & 310 (9\%) & 35 (10\%) & 211 (13\%) & 521 (11\%) \\ 
  Hyperlipidemia & 51652 (76\%) & 8476 (60\%) & 2290 (68\%) & 228 (66\%) & 1235 (77\%) & 3726 (81\%) \\ 
  Hypertension & 52303 (77\%) & 8586 (61\%) & 2357 (70\%) & 229 (66\%) & 1284 (80\%) & 3813 (83\%) \\ 
  Ischemic Heart Disease & 8028 (12\%) & 746 (5\%) & 313 (9\%) & 35 (10\%) & 201 (12\%) & 557 (12\%) \\ 
  Acute MI & 3353 (5\%) & 293 (2\%) & 135 (4\%) & 13 (4\%) & 82 (5\%) & 229 (5\%) \\ 
  Ischemic Stroke & 304 (0\%) & 29 (0\%) & 8 (0\%) & 2 (1\%) & 8 (0\%) & 21 (0\%) \\ 
  Major Depressive Disorder & 13235 (19\%) & 2997 (21\%) & 499 (15\%) & 54 (16\%) & 272 (17\%) & 1115 (24\%) \\ 
  Osteoporosis & 2654 (4\%) & 363 (3\%) & 106 (3\%) & 8 (2\%) & 61 (4\%) & 151 (3\%) \\ 
  Bariatric Surgery & 950 (1\%) & 504 (4\%) & 34 (1\%) & 11 (3\%) & 2 (0\%) & 66 (1\%) \\ 
  Metformin & 45453 (67\%) & 5403 (38\%) & 1953 (58\%) & 187 (54\%) & 970 (60\%) & 3404 (74\%) \\ 
  SGLT2i & 17052 (25\%) & 1690 (12\%) & 860 (26\%) & 53 (15\%) & 436 (27\%) & 1173 (26\%) \\ 
  DPP4 & 15173 (22\%) & 847 (6\%) & 659 (20\%) & 41 (12\%) & 342 (21\%) & 1313 (29\%) \\ 
  Sulfonylurea & 23689 (35\%) & 1414 (10\%) & 943 (28\%) & 78 (22\%) & 535 (33\%) & 1950 (43\%) \\ 
  Insulin & 9069 (13\%) & 760 (5\%) & 356 (11\%) & 25 (7\%) & 276 (17\%) & 675 (15\%) \\ 
  Orlistat & 52 (0\%) & 16 (0\%) & 1 (0\%) & 1 (0\%) & 1 (0\%) & 2 (0\%) \\ 
  Phentermine Topiramate & 90 (0\%) & 112 (1\%) & 3 (0\%) & 0 (0\%) & 3 (0\%) & 7 (0\%) \\ 
  BMI &  &  &  &  &  &  \\ 
    Mean (SD) & 36 (8.3) & 38 (8.4) & 36 (8.7) & 38 (9.4) & 33 (7.3) & 37 (8.4) \\ 
    Missing & 30839 (45.1\%) & 6978 (49.4\%) & 2221 (66.1\%) & 215 (61.8\%) & 1211 (75.1\%) & 1764 (38.5\%) \\ 
  Weight (in lbs) &  &  &  &  &  &  \\ 
    Mean (SD) & 230 (58) & 240 (56) & 230 (58) & 230 (61) & 210 (54) & 230 (58) \\ 
    Missing & 23286 (34.1\%) & 3606 (25.5\%) & 1628 (48.5\%) & 229 (65.8\%) & 600 (37.2\%) & 1640 (35.8\%) \\ 
  HbA1c &  &  &  &  &  &  \\ 
    Mean (SD) & 8.5 (1.9) & 6.8 (1.6) & 8.5 (1.9) & 7.9 (1.7) & 9.3 (2.0) & 8.8 (1.9) \\ 
    Missing & 14666 (21.5\%) & 5274 (37.4\%) & 823 (24.5\%) & 95 (27.3\%) & 390 (24.2\%) & 827 (18.0\%) \\ 
  \hline
\caption{Characteristics of patients first prescribed a GLP-1 RA, by brand for Dulaglutide, Tirzepatide, and Other.\Abbreviations: 
ADM=anti-diabetic medication,
AI  = American Indian, 
AN = Alaska Native, 
AOM=anti-obesity medication, 
Black = Black or African American, 
BMI = body mass index,
CKD=chronic kidney disease, 
COPD=chronic obstructive pulmonary disease, 
DPP4= dipeptidyl peptidase 4 inhibitor, 
FDA=Food and Drug Administration, 
HbA1c=hemoglobin A1C, 
MI=myocardial infarction, 
NH = Native Hawaiian, 
PI = Pacific Islander, 
SD=standard deviation, 
SGLT2i=sodium/glucose cotransporter-2 inhibitor,
T2D=type 2 diabetes mellitus.} 
\label{tab:table_1_brand_part2}
\end{longtable}
